Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies.

Roumi M, Lenaerts V, Boutignon F, Wuthrich P, Deghenghi R, Bellemare M, Adam A, Ong H

Peptides1 Jan 1995Cited by 4 (Europe PMC)

PMID8545255DOI10.1016/0196-9781(95)02022-oPepBankPUB-08545255

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In dogs, intravenous bolus hexarelin showed a terminal half-life of 120 min.
In plain wordsIn dogs, hexarelin given by IV injection had a long half-life of 120 minutes.
Peptide
Hexarelin
Outcome
Not applicableTerminal half-life after IV bolus
Study
dogn: not reported in source
Dogs
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 microgram/kg · intravenousAs given in this study (dog).
Measurements
Terminal half-life
120 min
IV 1 microgram/kg
Source sentences
Summary
Intravenous bolus pharmacokinetics of hexarelin displayed a high terminal half-life of 120 min, a fractional plasma clearance of 4.28 ml/min/kg, and a volume of distribution at steady state of 387.7 ml/kg.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
Report a problemFND-0854525505
02AnimalAnimal study (in vivo)Pharmacokinetics
In dogs, intravenous bolus hexarelin showed a fractional plasma clearance of 4.28 ml/min/kg.
In plain wordsIn dogs, hexarelin given by IV injection was cleared from plasma at 4.28 ml per minute per kg.
Peptide
Hexarelin
Outcome
Not applicableFractional plasma clearance after IV bolus
Study
dogn: not reported in source
Dogs
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 microgram/kg · intravenousAs given in this study (dog).
Measurements
Fractional plasma clearance
4.28 ml/min/kg
IV 1 microgram/kg
Source sentences
Summary
Intravenous bolus pharmacokinetics of hexarelin displayed a high terminal half-life of 120 min, a fractional plasma clearance of 4.28 ml/min/kg, and a volume of distribution at steady state of 387.7 ml/kg.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
Report a problemFND-0854525506
03AnimalAnimal study (in vivo)Pharmacokinetics
In dogs, intravenous bolus hexarelin showed a volume of distribution at steady state of 387.7 ml/kg.
In plain wordsIn dogs, hexarelin given by IV injection spread into a volume of 387.7 ml per kg.
Peptide
Hexarelin
Outcome
Not applicableVolume of distribution at steady state after IV bolus
Study
dogn: not reported in source
Dogs
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 microgram/kg · intravenousAs given in this study (dog).
Measurements
Volume of distribution at steady state
387.7 ml/kg
IV 1 microgram/kg
Source sentences
Summary
Intravenous bolus pharmacokinetics of hexarelin displayed a high terminal half-life of 120 min, a fractional plasma clearance of 4.28 ml/min/kg, and a volume of distribution at steady state of 387.7 ml/kg.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
Report a problemFND-0854525507
04AnimalAnimal study (in vivo)Pharmacokinetics
In dogs, clearance of subcutaneous hexarelin stayed constant over the 1 to 100 micrograms/kg dose range.
In plain wordsIn dogs, hexarelin was cleared at the same rate whether the injected dose was small or large.
Peptide
Hexarelin
Outcome
No significant changeClearance after SC dosing across doses
Study
dogn: not reported in source
Dogs
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1, 10 and 100 micrograms/kg · subcutaneousAs given in this study (dog).
Measurements
Clearance
3.93 to 5.17 ml/min/kg
SC 1-100 micrograms/kg
Source sentences
Summary
Following SC administration of hexarelin, despite the increase in dose administered, both clearance (3.93-5.17 ml/min/kg) and volume of distribution (316-544 ml/kg) parameters remained constant over the dose range studied.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
Report a problemFND-0854525508
05AnimalAnimal study (in vivo)Pharmacokinetics
In dogs, the volume of distribution of subcutaneous hexarelin stayed constant over the 1 to 100 micrograms/kg dose range.
In plain wordsIn dogs, hexarelin spread through the body to the same extent at small and large injected doses.
Peptide
Hexarelin
Outcome
No significant changeVolume of distribution after SC dosing across doses
Study
dogn: not reported in source
Dogs
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1, 10 and 100 micrograms/kg · subcutaneousAs given in this study (dog).
Measurements
Volume of distribution
316 to 544 ml/kg
SC 1-100 micrograms/kg
Source sentences
Summary
Following SC administration of hexarelin, despite the increase in dose administered, both clearance (3.93-5.17 ml/min/kg) and volume of distribution (316-544 ml/kg) parameters remained constant over the dose range studied.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
Report a problemFND-0854525509

Studies that did not test the peptide alone4

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

06LabNot a test of Hexarelin aloneIn vitro (cell-free)Other
A radioimmunoassay for hexarelin had a sensitivity of 1.34 fmol/assay.
In plain wordsIn lab tests, a new assay could detect hexarelin down to 1.34 fmol per assay.
Peptide
Hexarelin
Outcome
Not applicableRIA sensitivity
Study
n: not reported in source
Radioimmunoassay for hexarelin
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Assay sensitivity
1.34 fmol/assay
RIA
Source sentences
Summary
The sensitivity of the assay was determined to be 1.34 fmol/assay.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0854525501
07LabNot a test of Hexarelin aloneIn vitro (cell-free)Other
The antiserum cross-reacted with nine hexarelin analogues at less than 1% when positions 3, 4 or 5 were modified.
In plain wordsIn lab tests, the assay antiserum barely reacted with nine similar peptides, less than 1%.
Peptide
Hexarelin
Outcome
Not applicableRIA antiserum cross-reactivity with hexarelin analogues
Study
n: not reported in source
Radioimmunoassay for hexarelin
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Cross-reactivity
< 1%
nine hexarelin analogues
Source sentences
Summary
Cross-reactivity of the antiserum with nine hexarelin analogues was less than 1% upon modification of positions 3, 4, or 5 of the peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0854525502
08LabNot a test of Hexarelin aloneIn vitro (cell-free)Other
The radioimmunoassay showed no apparent cross-reaction with endogenous hexarelin metabolites.
In plain wordsIn lab tests, the assay did not react with the body's breakdown products of hexarelin.
Peptide
Hexarelin
Outcome
No significant changeRIA cross-reaction with endogenous hexarelin metabolites
Study
n: not reported in source
Radioimmunoassay for hexarelin
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
No apparent cross-reaction with endogenous hexarelin metabolites were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0854525503
09LabNot a test of Hexarelin aloneIn vitro (cell-free)Other
Intra- and interassay coefficients of variation of the radioimmunoassay were less than 3% and 4%.
In plain wordsIn lab tests, the assay gave repeatable results, with variation under 3% within runs and under 4% between runs.
Peptide
Hexarelin
Outcome
Not applicableRIA intra- and interassay variation
Study
n: not reported in source
Radioimmunoassay for hexarelin
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Intra-assay CV
< 3%
RIA
Interassay CV
< 4%
RIA
Source sentences
Summary
Intra- and interassay coefficients of variation were less than 3% and 4%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A radioimmunoassay (RIA) method for hexarelin, a peptidic growth hormone secretagogue, has been developed and applied to pharmacokinetic studies in dogs following an IV dose of 1 microgram/kg, and three SC doses of 1, 10, and 100 micrograms/kg.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0854525504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.